Tocagen Investigator Sponsored Trial (IST) Program

Tocagen IST program is open to qualified researchers who are interested in conducting their own research with our therapeutic candidates. Support is provided based on the scientific merit and rigor of proposals and whether it is in alignment with our areas of interest.

Our specific areas of interest are as follows:

  • Combination therapy (approved drugs and drugs in development) and its impact on mechanism of action (MoA) of Toca 511 & Toca FC in high grade glioma
  • Modified scheduling or administration of Toca 511, and Toca FC post-surgery in high grade glioma
  • Patients with specific gene mutations/alterations (e.g. IDH1/2 or unmethylated MGMT) or activations in high grade glioma patients
  • Other central nervous system (CNS) malignancies (e.g. Leptomeningeal disease, CNS lymphoma, high risk low grade glioma, tumor with H3K27 mutation)
  • Preclinical/translation research outside of CNS malignancies that help to better understand the MoA of Toca 511 & Toca FC

If you are interested in applying for this program, please complete the below form to download our IST form and send the completed IST form to ISTProgram@tocagen.com.  Please understand that Tocagen will review all inquiries, but may not be able to fulfill all such interests.

Click to Fill Out Form

Toca 511 & Toca FC are investigational products that have not been approved by any regulatory agency for commercial use.

Expanded Access to Investigational, Unapproved Medicines

We believe that our fastest path to fulfill our commitment to patients is to focus on working with the FDA to complete the required clinical studies needed to demonstrate safety and effectiveness of our investigational therapy Toca 511 & Toca FC for multiple cancer indications. This focus on completing our clinical trials will help us expeditiously achieve the best outcome for the greatest number of adults and children suffering from cancer.

Currently, Tocagen does not have an Expanded Access Program (EAP) for any advanced cancers. We plan to have an EAP once the data from our ongoing Toca 5 study is available for adults with recurrent High Grade Gliomas. In the interim, details of our ongoing clinical trials are available on the clinical trials section of our website. We encourage patients to discuss their treatment options, including clinical trials, with their medical team, and contact any of the several patient advocacy organizations listed below for resources, research and support.